News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

FDA Chastises Alexion Pharmaceuticals Inc. (ALXN) For Production Problems Again



8/27/2014 5:54:28 AM

free biotech news Get the latest biotech news where you want it. Sign up for the free GenePool newsletter today!

For the second time in two years, Alexion Pharmaceuticals ALXN +1.00% has run afoul of FDA inspectors, who cited the drug maker for lax manufacturing practices at a plant that makes its only marketed product, the pricey Soliris treatment for combating a rare blood disorder.

The agency cited the drug maker for three production issues found during an inspection this month, and these were separate from problems cited in a March 2013 warning letter that followed an earlier inspection in 2012, according to a filing with the U.S. Securities and Exchange Commission.

The FDA inspection report was not released, but Alexion disclosed that agency inspectors cited a need for “enhanced training around gowning procedures, more frequent environmental monitoring and processes related to identifying the definitive root cause of a prior” sterility failure.

Help employers find you! Check out all the jobs and post your resume.



comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES